About
Stephen Hilbert is a Seattle-based biotech business-development executive associated with both Oisin Biotechnologies and its oncology spinout OncoSenX. Company materials describe him as Chief Business Officer and a long-time business advisor focused on strategy and capital formation, with prior roles spanning Kineta, Immusoft, J.P. Morgan, and Charles Schwab. His public profile centers on helping preclinical gene-therapy companies build partnerships and financing pathways rather than deploying his own capital.
Areas of interest
longevitybiotechgene therapyoncologyage-related diseasesdrug developmentcapital formationbusiness strategy